BARDA, Regeneron Begin the First Clinical Trials of REGN-COV2, A Therapeutic two-antibody “Cocktail” for COVID-19 Patients

One of BARDA’s first private sector partners in the COVID-19 response, Regeneron, has begun the first clinical trials of REGN-COV2, its therapeutic two-antibody “cocktail” for COVID-19 patients. This treatment, developed with BARDA support, has the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2, the virus that causes COVID-19.

Our Therapeutic Portfolio